You are here

  • Home
  • Archive
  • Volume 16, Issue 4
  • Carrying one or two reduced-function CYP2C19 alleles is associated with an increased risk of major adverse cardiovascular events in people undergoing percutaneous coronary intervention and treated with clopidogrel

Article Text

Article menu
Download PDFPDF
Prognosis
Systematic review
Carrying one or two reduced-function CYP2C19 alleles is associated with an increased risk of major adverse cardiovascular events in people undergoing percutaneous coronary intervention and treated with clopidogrel

https://doi.org/10.1136/ebm1203

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • Competing interests ARS receives grant support from the National Institutes of Health to study the pharmacogenomics of antiplatelet agents. ARS is also a consultant for Bristol-Myers Squibb/Sanofi-aventis. AHR and JTD have no competing interests.